Conference
Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.
Abstract
336
Background: The prognostic impact of prior platinum agent (cisplatin vs. carboplatin) and site of primary (bladder vs. other) in the context of salvage therapy for advanced UC is unknown. Methods: We pooled 10 prospective phase II trials of ≥ second-line therapy for advanced UC with data recorded for prior platinum agent and site of primary in addition to major prognostic factors: TFPC (time from prior chemotherapy), Hb …
Authors
Sonpavde G; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A
Volume
32
Pagination
pp. 336-336
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2014
DOI
10.1200/jco.2014.32.4_suppl.336
Conference proceedings
Journal of Clinical Oncology
Issue
4_suppl
ISSN
0732-183X